MYOM2 and leukemia: In addition, DepOR has been investigated in hematologic malignancies to evaluate the changes of M-protein in multiple myeloma and minimal residual disease in leukemia and myeloma12-15, implying the validity of DepOR as a complementary endpoint established for different interventions and different neoplasms.